Comparison of Outcomes After Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction

• Published in: The American journal of cardiology 2020-12, Vol.136, p.62-70
• Main Authors: Aldaas, Omar M., Malladi, Chaitanya L., Mylavarapu, Praneet S., Lupercio, Florentino, Darden, Douglas, Han, Frederick T., Hoffmayer, Kurt S., Krummen, David, Ho, Gordon, Raissi, Farshad, Feld, Gregory K., Hsu, Jonathan C
• Format: Article
• Language: English
• Subjects: Ablation; Aged; Antiarrhythmics; Arrhythmia; Atrial Fibrillation - complications; Atrial Fibrillation - surgery; Cardiac arrhythmia; Cardiovascular disease; Catheter Ablation; Catheters; Cohort Studies; Complications; Confidence intervals; Congestive heart failure; Ejection fraction; Female; Fibrillation; Fistula; Heart failure; Heart Failure - complications; Heart Failure - physiopathology; Hospitalization; Humans; Male; Medical instruments; Middle Aged; Mortality; Radio frequency; Retrospective Studies; Stroke Volume; Treatment Outcome; Variables
• ISSN: 0002-9149; 1879-1913; 1879-1913
• DOI: 10.1016/j.amjcard.2020.09.018

Catheter ablation improves outcomes in atrial fibrillation (AF) patients with heart failure (HF) with reduced ejection fraction (HFrEF). We sought to evaluate the efficacy and safety of catheter ablation of AF in HF patients with a preserved ejection fraction (HFpEF). We performed a retrospective study of all patients who underwent de novo radiofrequency catheter ablation enrolled in the UC San Diego AF Ablation Registry. The primary outcome was recurrence of all atrial arrhythmias on or off antiarrhythmic drugs (AAD). Of 547 total patients, 51 (9.3%) had HFpEF, 40 (7.3%) had HFrEF, and 456 (83.4%) were without HF. There was no difference in recurrence of atrial arrhythmias on or off AAD (Adjusted Hazard Ratio [AHR] 1.92 [95% CI 0.97 to 3.83] for HFpEF vs HFrEF and AHR 0.90 [95% CI 0.59 to 1.39] for HFpEF vs no HF) or off AAD (AHR 1.96 [95% CI 0.99 to 3.90] for HFpEF vs HFrEF and AHR 1.14 [95% CI 0.74 to 1.77] for HFpEF vs no HF). There was also no difference in rates of all-cause hospitalizations (AHR 1.80 [95% CI 0.97 to 3.33] for HFpEF vs HFrEF and AHR 2.05 [95% CI 1.30 to 3.23] for HFpEF vs no HF) or rates of all-cause mortality (AHR 0.53 [95% CI 0.05 to 6.11] for HFpEF vs HFrEF and AHR 2.46 [95% CI 0.34 to 17.92] for HFpEF vs no HF). There were no significant differences in AAD use (p = 0.176) or procedural complications between groups (p = 0.980). In conclusion, there were no significant differences in arrhythmia-free survival between patients with HFpEF and HFrEF that underwent catheter ablation of AF.